ABSTRACT
A variety of cells can secrete exosomes which contain abundant contents including proteins,lipids and nucleic acids. Under physiological and pathological conditions,exosomes and their contents can mediate intercellular material transportation and signal transduction， thereby participating in cell proliferation and apoptosis,migration and differentiation， tumor invasion and metastasis， inflammation and other processes. Studies have shown that exosomes can participate in the pathological process of lung diseases meanwhile,exosomes and their contents can be used as newtargets for the diagnosis， treatment and prognosis of lung diseases. Therefore， exosomes have arresting potential for clinical applications in lung diseases.
ABSTRACT
Multisystem inflammatory syndrome in children (MIS-C) is a type of hyperinflammatory symptoms similar to Kawasaki disease after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and is commonly observed in children aged 8-10 years. Primary therapeutic medications for MIS-C are intravenous immunoglobulins and glucocorticoids. It has been reported that biologics, such as IL-1 receptor antagonist anakinra, IL-6 receptor antagonist tocilizumab, and TNF-α receptor antagonist infliximab, can be used as an option for critically ill patients. This article elaborates on the mechanism of action of the above biologics and discusses the efficacy and safety biologics in the treatment of MIS-C after SARS-CoV-2 infection, in order to provide methods for the treatment of MIS-C with severe symptoms.
